{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:50:31Z","timestamp":1776869431760,"version":"3.51.2"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>The primary objective was to determine the response rate in patients with metastatic pancreatic cancer treated in first line with irinotecan\/docetaxel combination (Arm A) or with irinotecan\/docetaxel\/cetuximab combination (Arm B). Secondary endpoints were progression-free survival (PFS), overall survival (OS), toxicity, and the rate of thromboembolic events with prophylactic enoxaparin sodium.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Patients were eligible who had measurable, metastatic adenocarcinoma of the pancreas, and normal bilirubin. All patients received anticoagulation. Docetaxel (35 mg\/m<jats:sup>2<\/jats:sup>) and irinotecan (50 mg\/m<jats:sup>2<\/jats:sup>) were administered once a week for 4 weeks followed by 2 weeks rest (Arm A) alone or with the addition of cetuximab (Arm B). The primary endpoint was response rate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 87 eligible patients were enrolled and treated. Grade 3\/4 toxicity was observed in 74% of patients in Arm A and 76% in Arm B. The principal grade 3\/4 toxicity was diarrhea. Response rates were 4.5% in Arm A and 7% in Arm B. Median PFS and OS were 3.9 and 6.5 months in Arm A and 4.5 and 5.4 months in Arm B.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Docetaxel\/irinotecan combination is associated with considerable toxicity. Objective responses were infrequent and addition of cetuximab in an unselected population was not beneficial, but PFS and OS were comparable with those achieved with other regimens. Docetaxel\/irinotecan therapy is active in metastatic pancreatic cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000068","type":"journal-article","created":{"date-parts":[[2014,3,31]],"date-time":"2014-03-31T16:41:48Z","timestamp":1396284108000},"page":"340-345","source":"Crossref","is-referenced-by-count":20,"title":["Randomized Phase II Trial of Irinotecan\/Docetaxel or Irinotecan\/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer"],"prefix":"10.1097","volume":"39","author":[{"given":"Barbara","family":"Burtness","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fox Chase Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Powell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Berlin","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darla K.","family":"Liles","sequence":"additional","affiliation":[{"name":"East Carolina University School of Medicine, Greenville, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E.","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Thomas Jefferson University School of Medicine, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Thomas Jefferson University School of Medicine, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al B.","family":"Benson","sequence":"additional","affiliation":[{"name":"Lurie Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230905","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R3-20230905","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","article-title":"Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma","volume":"21","author":"Tempero","year":"2003","journal-title":"J Clin Oncol"},{"key":"R4-20230905","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1158\/1535-7163.MCT-06-0004","article-title":"Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer","volume":"5","author":"Giovannetti","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"R5-20230905","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20230905","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R7-20230905","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"J Clin Oncol"},{"key":"R8-20230905","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.10323","article-title":"Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and\/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia del l\u2019Italia Meridionale","volume":"94","author":"Colucci","year":"2002","journal-title":"Cancer"},{"key":"R9-20230905","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol"},{"key":"R10-20230905","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1081\/CNV-120002146","article-title":"Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy","volume":"20","author":"Lenzi","year":"2002","journal-title":"Cancer Invest"},{"key":"R11-20230905","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0959-8049(00)00072-1","article-title":"Phase II study of docetaxel as first line chemotherapy for advanced pancreatic adenocarcinoma","volume":"36","author":"Rougier","year":"2000","journal-title":"Eur J Cancer"},{"key":"R12-20230905","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","article-title":"Phase II trial of CPT11, irinotecan hydrochloride, in patients with advanced pancreatic cancer, an EORTC early clinical trials group study","volume":"6","author":"Wagener","year":"1995","journal-title":"Ann Oncol"},{"key":"R13-20230905","first-page":"378","article-title":"In vivo evaluation of the docetaxel-irinotecan combination","volume":"37","author":"Bissery","year":"1996","journal-title":"Proc Am Assoc Cancer Res"},{"key":"R14-20230905","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00001813-199703000-00003","article-title":"Effect of CPT-11 in combination with other anticancer agents in lung cancer cells","volume":"8","author":"Pei","year":"1997","journal-title":"Anticancer Drugs"},{"key":"R15-20230905","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002800050790","article-title":"In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines","volume":"42","author":"Kano","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"R16-20230905","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/cbt.314","article-title":"Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer","volume":"1","author":"Bleickardt","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"R17-20230905","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1200\/JCO.2000.18.5.1116","article-title":"Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity","volume":"18","author":"Adjei","year":"2000","journal-title":"J Clin Oncol"},{"key":"R18-20230905","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2000.18.20.3545","article-title":"Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors","volume":"18","author":"Couteau","year":"2000","journal-title":"J Clin Oncol"},{"key":"R19-20230905","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/PPO.0b013e31813c1174","article-title":"Phase II trial of weekly docetaxel\/irinotecan combination in advanced pancreatic cancer","volume":"13","author":"Burtness","year":"2007","journal-title":"Cancer J"},{"key":"R20-20230905","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1081\/CNV-200032929","article-title":"Salvage chemotherapy with mitomycin, docetaxel and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial","volume":"22","author":"Reni","year":"2004","journal-title":"Cancer Invest"},{"key":"R21-20230905","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/00006676-200407000-00061","article-title":"The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma","volume":"29","author":"Ueda","year":"2004","journal-title":"Pancreas"},{"key":"R22-20230905","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"R23-20230905","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2004.12.040","article-title":"Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial","volume":"22","author":"Xiong","year":"2004","journal-title":"J Clin Oncol"},{"key":"R24-20230905","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2009.25.7550","article-title":"Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group directed intergroup trial S0205","volume":"28","author":"Philip","year":"2010","journal-title":"J Clin Oncol"},{"key":"R25-20230905","first-page":"353","article-title":"Multirow detector CT detection of subclinical visceral and pulmonary thrombosis in advanced pancreatic cancer is an adverse prognostic indicator","volume":"22","author":"Zawin","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R26-20230905","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(04)01606-7","article-title":"Pancreatic cancer and thromboembolic disease","volume":"5","author":"Khorana","year":"2004","journal-title":"Lancet Oncol"},{"key":"R27-20230905","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jnci\/86.6.446","article-title":"Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea","volume":"86","author":"Abigerges","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"R28-20230905","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R29-20230905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"R30-20230905","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R31-20230905","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/cncr.27619","article-title":"An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment","volume":"119","author":"Fisher","year":"2013","journal-title":"Cancer"},{"key":"R32-20230905","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-07-0560","article-title":"Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus","volume":"13","author":"Riely","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201608000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:37:13Z","timestamp":1693957033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201608000-00005"}},"subtitle":["An Eastern Cooperative Oncology Group Study"],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000068","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}